TLTFF (Theralase Technologies) Risk Assessment


TLTFF Theralase Technologies Inc TLTFF
46 GF Score
Price $0.19
GF Value $0.13
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Theralase Technologies Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Theralase Technologies is: High Risk: High uncertainty with risk-return tradeoff.

Theralase Technologies  (OTCPK:TLTFF) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Theralase Technologies Risk Assessment Related Terms

TLTFF vs ABT, SYK, MDT: Risk Assessment Comparison

For the Medical Devices subindustry, Theralase Technologies's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Theralase Technologies Risk Assessment vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Theralase Technologies's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Theralase Technologies's Risk Assessment falls into.


TLTFF
46GF Score
Theralase Technologies Inc TLTFF
Risk Assessment is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Theralase Technologies (TLTFF) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of $0.19 is trading 49.1% above its estimated GF Value™ of $0.13. GuruFocus considers Theralase Technologies to be Significantly Overvalued.

Key valuation signals for TLTFF:

  • Risk Assessment:
  • GF Value™: $0.13 vs. price of $0.19 (49.1% above fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theralase Technologies Business Description

Other Exchanges TTX:GermanyTLT:Canada
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score

Get the complete analysis for TLTFF

Risk Assessment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price
$0.13
GF Value